Printer Friendly

SPECTRAL DIAGNOSTICS SCIENTISTS TO PRESENT THREE ABSTRACTS AT NATIONAL MEETING OF AMERICAN ASSOCIATION OF CLINICAL CHEMISTRY JULY 11-15, 1993

 TORONTO, May 17 /PRNewswire/ -- Spectral Diagnostics Inc. (NASDAQ: DIAGF), the developer of a systems approach to cardiac diagnostics, reported today that the Contributed Papers Committee of the American Association of Chemistry, Inc. has accepted three abstracts by Spectral scientists for presentation at the AACC's 45th National Meeting in New York, July 11 - 15, 1993. Spectral scientists will be presenting data relating to the company's unique cardiac markers and their clinical utility.
 Two of the accepted abstracts will be presented by Miyoko Takahashi -- "Development of Unique Monoclonals to Chicken Egg Yolk Immunoglobulins" and "Development and Characterization of Monoclonal Antibodies Specific for Human Cardiac Troponin."
 The third abstract, "A New Mono-Poly Antibody Combination Used In An Elisa Assay For Human Myoglobin," will be presented by Dr. V. Blavans.
 In making the announcement, Douglas C. Ball, chairman, Spectral Diagnostics, said, "We are pleased with the recognition of the high calibre of Spectral's cardiac diagnostic research that is reflected in the acceptance of three abstracts for presentation by Spectral scientific researchers at the prestigious National Meeting of the American Association of Clinical Chemistry."
 The American Association for Clinical Chemistry, Inc., is a non-profit, international organization with 10,000 members in clinical chemistry, biochemistry and immunology; medical technology, pathology and toxicology; and laboratory management, sales and research and development. The primary professional interest of AACC members is applying the science of chemistry to the diagnosis and treatment of disease and the assessment of patient health.
 Spectral Diagnostics Inc., Toronto has developed a systems approach to cardiac diagnostics that includes its proprietary Cardiac Panel. The Cardiac Panel distinguishes, for the first time, heart from non-heart ailments and unstable angina from a myocardinal infarction (heart attack) -- without the use or dependence on expensive laboratory equipment. The Cardiac Panel, slightly larger than a credit card, is easy to use, requires only a few drops of a patient's blood and provides a differential diagnosis in approximately 8 minutes. Patent applications have been filed in 18 countries. The Cardiac Panel, in combination with Spectral's library of cardiac proteins and antibodies, will complete the systems approach to cardiac diagnostics. Clinical trials are underway. Upon completion of the clinical trials, Spectral will file for FDA approval of the Cardiac Panel. Spectral also is distinguished as being the world's largest single source and developer of cardiac proteins and antibodies.
 Spectral's common shares are listed on the NASDAQ Exchange in the United States and the Canadian Dealing Network (CDN) in Canada. Spectral's trading symbols are DIAGF (common shares) and DIAGWF (redeemable warrants) on the NASDAQ Exchange and SPTR (common shares) and SPTR.WT (redeemable warrants) on the Canadian Dealing Network (CDN).
 -0- 5/17/93
 /CONTACT: Douglas C. Ball, chairman and chief executive officer, or Dr. George Jackowski, president and director of Research of Spectral Diagnostics Inc., 416-626-3233, or Irving L. Straus, chairman of Straus Corporate Communications, 212-768-2477, for Spectral Diagnostics Inc./
 (DIAGF)


CO: Spectral Diagnostics Inc. ST: Ontario IN: MTC SU:

TS-OS -- NY066 -- 9223 05/17/93 12:42 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 17, 1993
Words:497
Previous Article:ADELPHIA CABLE AND THE WEATHER CHANNEL OFFER ASSISTANCE TO MIAMI CHILDREN
Next Article:PACIFIC ANIMATED IMAGING ANNOUNCES TRW RELATIONSHIP
Topics:


Related Articles
NATIONAL RESEARCH COUNCIL CANADA APPROVALS CDN. $348,000 TO SPECTRAL DIAGNOSTICS
SPECTRAL DIAGNOSTICS INC. REPORTS RESULTS FOR THIRD FISCAL QUARTER AND NINE MONTHS ENDED DEC. 31, 1993
SPECTRAL DIAGNOSTICS TO PRESENT NINE ABSTRACTS AT NATIONAL MEETING OF AMERICAN ASSOCIATION OF CLINICAL CHEMISTRY, JULY 17-21, 1994
SPECTRAL DIAGNOSTICS INC. REPORTS RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 1994
SPECTRAL ANNOUNCES ACQUISITION OF HUMAN CARDIAC GENE BANK AND CLINICAL EVALUATION OF ADDITIONAL PATENTABLE CARDIAC MARKERS
ABSTRACTS SUPPORT THE COMMERCIAL LAUNCH OF SPECTRAL'S CARDIAC STATus CK-MB/MYOGLOBIN PANEL TEST
Spectral Diagnostics Inc. Receives FDA Marketing Clearance for its Cardiac STATus(TM) Point of Care, Rapid Format Troponin I Panel Test
Lifestream to Present Scientific Abstract at American Association for Clinical Chemistry 51st Annual Meeting.
New CEO at Spectral Genomics, Inc.
Changes in academic productivity: implications for clinical laboratory research and development.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters